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Abstract
OBJECTIVE: To observe the therapeutic effect of
Chishaodanpi decoction (CSDPD) on chronic viral
cholestatic hepatitis.
METHODS: A total of 107 subjects with chronic vi-
ral cholestatic hepatitis were enrolled in our hospi-
tal from March 2007 to November 2012. Patients
were randomly divided into treatment (54 cases)
and control groups (53 cases). The control group
was treated with potassium magnesium aspartate,
diammonium glycyrrhizinate, glucurolactone, vita-
min C, and lamivudine, once a day. The treatment
group was treated with modified CSDPD, 100 mL a
time, twice a day, in addition to the treatment giv-
en to the control group. The patients in both
groups were treated for 8 weeks. The main symp-
toms and signs were recorded every day through-
out the clinical trial. Before and after the trial,
changes in liver function including total bilirubin
(TBil), direct bilirubin (DBil), total bile acid (TBA),
and the activities of alkaline phosphatase (ALP), ala-
nine aminotransferase (ALT), aspartate aminotrans-
ferase (AST), and γ-glutamyl transferase (γ-GT),
were all detected. Adverse reactions were also re-
corded.
RESULTS: There were no differences in gender, age,
disease duration, symptoms, signs, or laboratory
findings between the two groups (P>0.05). After an
8-week treatment, improvements in jaundice, weak-
ness, poor appetite, abdominal distention, and skin
itching were significantly better in the treatment
group than in the control group (P<0.05). In the
treatment group, 43 patients had a significant re-
sponse to the treatment, seven patients had a re-
sponse, and four patients had no response, with 21,
12, and 20 patients in the control group, respective-
ly. The total effective rate was 92.6% in the treat-
ment group and 62.3% in the control group, which
was a significant difference (P<0.05). The levels of
TBil, DBil, TBA, ALP, ALT, AST, and γ-GT in both
groups were significantly lower after treatment,
and were significantly different between the two
groups (P<0.05). A few patients in the treatment
group had mild adverse effects such as increased
bowel movement frequency and mild stomach-
ache. No other adverse reactions were observed in
either group.
CONCLUSION: CSDPD has a satisfactory therapeu-
tic effect on chronic viral cholestatic hepatitis.
© 2014 JTCM. All rights reserved.
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INTRODUCTION
Cholestatic hepatitis, a liver disease that often results
from chronic viral hepatitis, is mainly characterized by
intrahepatic cholestasis, long durations of jaundice,
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poor appetite, skin itching, clay-colored stools, and in-
creased levels of total bilirubin (TBil), direct bilirubin
(DBil), total bile acid (TBA), and activities of alkaline
phosphatase (ALP) and γ-glutamyl transferase
(γ-GT).1-2 Cholestatic hepatitis can develop into fulmi-
nant hepatitis or cholestatic cirrhosis, which can in-
crease patient mortality. Therefore, creating effective
treatments for cholestatic hepatitis and slowing the
progress of cirrhosis and its complications are problems
that need to be solved.3 Protecting the liver, promoting
bile flow, relieving jaundice, and resisting viral infec-
tion are the treatment strategies used in clinical prac-
tice for cholestatic hepatitis. However, conventional
Western Medicine is not very efficacious, and treat-
ments are expensive.4 For example, studies have shown
that the first-line drug for cholestatic hepatitis, ursode-
oxycholic acid, had no differences in the improvement
of clinical symptoms, such as weakness and abdominal
distention, compared to placebo.5
Chronic viral cholestatic hepatitis, characterized under
"jaundice" in Traditional Chinese Medicine (TCM),6
is caused by damp-heat attack, which leads to toxic
heat spreading throughout the body. The stagnation of
toxic heat in the blood leads to blood heat stroke and
blood stasis, resulting in a gradual exacerbation of jaun-
dice. Therefore, the pathogenic basis for cholestatic
hepatitis is stagnated blood and heat, and the therapeu-
tic principle of activating blood, clearing heat, and re-
moving toxins is used for treatment.7-14 Reports indi-
cate that TCMs that protect the liver and relieve jaun-
dice are effective in treating chronic cholestatic hepati-
tis, and herbs such as Chishao (Radix Paeoniae Rubra)
are commonly used to clear heat, remove toxins, and
cool blood.15 He et al 16 used Chidantuihuang granules
to treat acute and chronic viral cholestatic hepatitis
with satisfactory curative effects.
In this study, modified Chishaodanpi decoction (CSD-
PD) was used to treat chronic viral cholestatic hepatitis
compared with conventional therapy. The results
could serve as a reference for the clinical treatment of
chronic viral cholestatic hepatitis.
MATERIALS ANDMETHODS
Recruitment of participants
A total of 107 participants meeting the diagnostic crite-
ria for viral hepatitis and cholestatic hepatitis.17 Pa-
tients with alcohol- or drug-induced cholestatic hepati-
tis, and cholestatic hepatitis resulting from extrahepatic
biliary obstruction, were excluded from this trial. The
107 patients (74 subjects with hepatitis B and 33 with
hepatitis C) were randomly divided into a treatment
group (54 cases) and a control group (53 cases). This
study was approved by the ethics committee of the
150th Hospital of PLA. All patients signed an in-
formed consent form.
Treatment
The patients in both groups were conventionally treat-
ed with potassium magnesium aspartate (30 mL), di-
ammonium glycyrrhizinate (30 mL), glucurolactone
(0.4 g), vitamin C (2.0 g), and lamivudine (100 mg, an
antiviral drug), once a day. In addition, patients in the
treatment group took modified CSDPD, 100 mL oral-
ly, twice a day in the morning and evening. The decoc-
tion consisted of Chishao (Radix Paeoniae Rubra)
60-120 g (over 180 g for severe cases), Yinchen (Herba
Artemisia Capillaris) 30 g, Zhizi (FructusGardeniae) 30 g,
Dahuang (Radix Et Rhizoma Rhei Palmati) 10 g, Dan-
shen (Radix Salviae Miltiorrhizae) 25 g, Mudanpi (Cor-
tex Moutan Radicis) 25 g, Dihuang (Radix Rehmanni-
ae) 25 g, Zexie (Rhizoma Alismatis) 15 g, Dangshen
(Radix Codonopsis) 15 g, Banxia (RhizomaPinelliae) 10 g,
Fuling (Poria) 25 g, Baizhu (Rhizoma Atractylodis Mac-
rocephalae) 25 g, Cheqianzi (Semen Plantaginis) 30 g,
and prepared Gancao (Radix Glycyrrhizae) 6 g. For Yin
jaundice, prepared Fuzi (Radix Aconiti Lateralis Prepara-
ta), Ganjiang (Rhizoma Zingiberis), and Guizhi (Ramu-
lus Cinnamomi) were added to warm the middle Jiao
and disperse cold. For skin itching, Difuzi (Fructus Ko-
chiae Scopariae), Jingjie (Herba Schizonepetae Tenuifoli-
ae), Baixianpi (Cortex Dictamni Radicis), and Fangfeng
(Radix Saposhnikoviae) were added to dispel wind and
relieve itching. The herbal decoction was prepared by
the Pharmaceutical Factory of the 150th Hospital of
Chinese People's Liberation Army. Both groups were
treated for 8 weeks.
Indexes of observation
Changes in jaundice, weaknesses, poor appetite, ab-
dominal distention, skin itching, and adverse reactions
were observed and recorded before and after treatment.
The levels of TBil, DBil, TBA, and activities of ALP,
ALT, AST, and -GT were determined before and after
treatment.
Criteria for evaluating curative effect
A "significant effect" indicated relief of jaundice, weak-
nesses, poor appetite, abdominal distention, and skin
itching, and normalization or more than 50% improve-
ment in biochemical indexes of liver function. "Effec-
tive" indicated significant alleviation of jaundice, weak-
nesses, poor appetite, abdominal distention, and skin
itching, and more than 25% and less than 50% im-
provement of biochemical indexes of liver function.
"Ineffective" indicated no improvement, or exacerba-
tion of symptoms.18 The total effective rate was consid-
ered as all patients experiencing a significant effect and
patients experiencing effective treatment divided by
the total number of patients.
Statistical analysis
The statistical software SPSS 13.0 (Chicago, IL, USA)
was used for analysis of experimental data. Analysis of
variance and covariance was used to determine whether
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there were significant differences between the two
groups. In descriptive analyses, continuous variables
were expressed as mean±standard deviation (SD) or me-
dian (interquartile range), and categorical variables as
absolute figures and percentages. Comparison of the
measurement data was analyzed by t-test, and count da-
ta were analyzed by χ2 test. P-values less than 0.05
were considered statistically significant.
RESULTS
Patient information
Among the 54 patients in the treatment group were 35
males and 19 females, aged 23-67 years, (49±10) years
on average, with a disease duration of 7-24 months,
(15±6) months on average. Among the 53 patients in
the control group were 32 males and 21 females, aged
24-69 years, (50±9) years on average, with a disease du-
ration of 6-23 months, (15 ± 7) months on average.
There were no significant differences in gender, age,
disease duration, symptoms, signs, or laboratory find-
ings between the two groups (P>0.05,Tables 1-3).
Improvements in main symptoms and signs
After treatment, improvements in jaundice, weakness,
poor appetite, abdominal distention, and skin itching
were significantly better in the treatment group than
those in the control group (P<0.05, Table 4).
Comparison of clinical effects
In the treatment group, there was a significant effect in
43 patients, effective treatment in seven patients, and
ineffective treatment in four patients. In the control
group, there was a significant effect in 21 patients, ef-
fective treatment in 12 patients, and ineffective treat-
ment in 20 patients. The total effective rate was 92.6%
in the treatment group and 62.3% in the control
group,which is significantly different (P<0.05) (Table 5).
Changes in laboratory findings of liver function
before and after treatment
After treatment, the liver function of both groups im-
proved significantly (P<0.05). The liver function im-
provement was significantly greater in the treatment
group than in the control group (P<0.05) (Table 6).
Adverse reactions
Patients in the control group had no obvious adverse
reactions. Three patients in the treatment group had
mild adverse reactions such as increased bowel move-
ment frequency and mild stomachache in the first
week of treatment. However, the patients could toler-
ate the adverse reaction. The mild adverse reactions
gradually disappeared as treatment continued. All pa-
tients finished the treatment.
DISCUSSION
Chronic viral cholestatic hepatitis, which is mainly
Group
Control
Treatment
n
53
54
Age range
(years)
24-69
23-67
Average age
(years)
50±9
49±10
Gender [(n) %]
Male
32 (60.37)
35 (64.81)
Female
21 (39.62)
19 (35.19)
Average disease
duration (month)
15±7
15±6
Notes: control group was treated with conventional Western Medicine. Treatment group was treated with modified CSDPD in addition
to conventional Western Medicine. CSDPD: Chishaodanpi decoction. There were no significant differences in gender, age, or average dis-
ease duration between the two groups before treatment (P>0.05).
Table 1 Comparison of general data between the two groups before treatment
Group
Treatment
Control
n
54
53
Weakness
51 (94.4)
49 (92.4)
Abdominal distention
35 (64.8)
34 (64.1)
Poor appetite
41 (75.9)
42 (79.2)
Skin itching
34 (62.9)
32 (60.4)
Jaundice
54 (100.0)
53 (100.0)
Notes: control group was treated with conventional Western Medicine. Treatment group was treated with modified CSDPD in addition
to conventional Western Medicine. CSDPD: Chishaodanpi decoction. There were no significant differences in the symptoms and signs
between the two groups before treatment (all P>0.05).
Table 2 Comparison of symptoms and signs between the two groups before treatment [(n) %]
Group
Control
Treatment
n
53
54
TBA
(μmol/L)
55±4
56±5
TBiL
(μmol/L)
179±34
182±39
DBiL
(μmol/L)
132±28
128±25
ALT
(U/L)
297±19
301±21
AST
(U/L)
123±59
134±60
ALP
(U/L)
357±59
350±53
γ-GT
(U/L)
413±83
406±90
Table 3 Comparison of laboratory findings in liver function between the two groups before treatment ( xˉ ±s)
Notes: control group was treated with conventional Western Medicine. Treatment group was treated with modified CSDPD in addition
to conventional Western Medicine. TBil: total bilirubin; DBil: direct bilirubin; TBA: total bile acid; ALP: activities of alkaline phospha-
tase; γ-GT: γ-glutamyl transferase; ALT: alanine aminotransferase; AST: aspartate aminotransferase; CSDPD: Chishaodanpi decoction.
There were no significant differences in the levels of TBil, DBil, TBA, ALP, ALT, AST, and γ-GT between the two groups before treat-
ment (all P>0.05).
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characterized by intrahepatic cholestasis, results from
necrosis of hepatic cells, blockage of bile, and eventual
obstruction of bile capillaries in the portal area.19 In pa-
tients with chronic viral cholestatic hepatitis, there are
significant increases in serum bilirubin (mainly DBil)
and activities of ALP and γ-GT. During cholestasis, it
is difficult to treat jaundice with the usual treatments
such as protecting the liver, promoting bile flow, and
improving liver enzyme levels, and there is no specific
treatment for the disease. Prolonged cholestasis can
lead to cirrhosis and eventually liver and kidney fail-
ure.20
Chronic viral cholestatic hepatitis, which is character-
ized as "jaundice" in TCM,6 is caused by excessive
damp-heat, which leads to toxic heat spreading
throughout the body. The stagnation of toxic heat in
the blood forms blood stasis, which causes a gradual ex-
acerbation of jaundice. Therefore, the pathogenic basis
for the disease is stagnated blood and heat. The thera-
peutic principle of activating blood, clearing heat, re-
moving toxins, and inducing purgation should be used
to treat chronic viral cholestatic hepatitis.7-14
In the CSDPD prescription, Chishao (Radix Paeoniae
Rubra), Mudanpi (Cortex Moutan Radicis), Danshen
(Radix Salviae Miltiorrhizae), and Dihuang (Radix
Rehmanniae) can cool and activate the blood. Dangsh-
en (Radix Codonopsis), Banxia (Rhizoma Pinelliae), and
Baizhu (Rhizoma Atractylodis Macrocephalae) can invig-
orate the spleen and harmonize the stomach. Yinchen
(Herba Artemisia Capillaris), Zhizi (Fructus Gardeniae),
Fuling (Poria), Zexie (Rhizoma Alismatis), Cheqianzi
(Semen Plantaginis), and Dahuang (Radix Et Rhizoma
Rhei Palmati) can clear heat and drain dampness to pro-
mote the elimination of damp-heat from the excre-
ment and urine. Prepared Gancao (Radix Glycyrrhizae)
can harmonize the other drugs in the prescription. Ch-
ishao (Radix Paeoniae Rubra), a blood-activating and
stasis-resolving herb, acts on the liver meridian to enter
the blood, remove heat, eliminate stasis, and purge liv-
er-fire. Clinical practice shows that Chishao (Radix Pae-
Group
Treatment
Control
n
54
53
Treatment
Before
After
Before
After
Weakness
51 (94.4)
13 (24.1)ab
49 (92.4)
24 (45.3)a
Abdominal distention
35 (64.8)
9 (16.7)ab
34 (64.1)
21 (39.6) a
Poor appetite
41 (75.9)
12 (22.2)ab
42 (79.2)
25 (47.2) a
Skin itching
34 (62.9)
8 (14.8)ab
32 (60.4)
19 (35.8) a
Jaundice
54 (100.0)
11 (20.3)ab
53 (100.0)
23 (43.4)a
Notes: control group was treated with conventional Western Medicine. Treatment group was treated with modified CSDPD and conven-
tional Western Medicine. CSDPD: Chishaodanpi decoction. aP<0.05, compared with the datum in the same group before treatment, bP<
0.05, compared with the datum in the control group.
Table 4 Comparison of improvement of signs and symptoms between the two groups [(n) %]
Group
Treatment
Control
n
54
53
Significant effect
43 (79.6)
21 (39.6)
Effectiveness
7 (13.0)
12 (22.6)
Ineffectiveness
4 (7.4)
20 (37.7)
Total effective rate
92.6a
62.3
Notes: control group was treated with conventional Western Medicine. Treatment group was treated with modified CSDPD and conven-
tional Western Medicine. CSDPD: Chishaodanpi decoction. aP<0.05, compared with the datum in the control group.
Table 5 Comparison of efficacy between the two groups [(n) %]
Notes: control group was treated with conventional Western Medicine. Treatment group was treated with modified CSDPD and conven-
tional Western Medicine. TBil: total bilirubin; DBil: direct bilirubin; TBA: total bile acid; ALP: activities of alkaline phosphatase; γ-GT:γ-glutamyl transferase; ALT: alanine aminotransferase; AST: aspartate aminotransferase; CSDPD: Chishaodanpi decoction. Compared
with the datum before treatment in the same group, aP<0.05; compared with the datum after treatment in the control group, bP<0.05.
Liver function
TBA (μmol/L)
TBiL (μmol/L)
DBiL (μmol/L)
ALT (U/L)
AST (U/L)
ALP (U/L)
γ-GT (U/L)
Treatment (n=54)
Before treatment
55.8±5.2
181.5±38.6
127.8±25.2
300.8±21.2
133.6±60.1
349.8±53.4
406.5±90.4
After treatment
12.0±1.7ab
41.5±19.6ab
21.8±7.9ab
69.2±10.8ab
47.3±28.1ab
66.7±31.6ab
57.5±41.1ab
Control (n=53)
Before treatment
54.6±3.8
178.8±34.5
131.6±27.8
296.7±19.4
122.8±59.2
356.7±58.6
413.1±83.4
After treatment
40.2±2.1a
82.8±20.7a
43.5±12.5a
102.4±15.6a
58.5±25.2a
89.7±33.4a
97.3±31.6a
Table 6 Comparison of liver function before and after treatment in the same group and after treatment between the two groups
( xˉ ±s)
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oniae Rubra) and Mudanpi (Cortex Moutan Radicis) at
large dosages can significantly improve jaundice. Mod-
ern pharmacological studies indicate that total Paeonia
glycosides, a main component of Chishao (Radix Pae-
oniae Rubra), can cool and activate blood, resolve sta-
sis, lower blood viscosity, relieve endotoxemia, remove
jaundice, inhibit the production of plasma thrombox-
ane, improve liver microcirculation, prevent liver fibro-
sis, and promote the repair and regeneration of injured
liver cells. Therefore, Paeonia glycosides have an excel-
lent therapeutic effect on cholestatic hepatitis.21-23 Mu-
danpi (Cortex Moutan Radicis) is a bitter and pungent
herb that is slightly cold in nature, and is mainly used
to treat pathogenic heat attacking the blood, and blood
stasis. The therapeutic action of Mudanpi (Cortex Mou-
tan Radicis) is related to the heart, liver, and kidney me-
ridians and it can clear heat from the blood, promote
blood circulation, and remove blood stasis. Coumarin,
an active ingredient of Yinchen (Herba Artemisia Capil-
laris), can protect hepatic cell membranes, prevent he-
patic necrosis, promote liver cell regeneration, improve
liver microcirculation, inhibit glucuronidase activity,
strengthen liver detoxifying activity, and dilate the bile
duct.24,25 6,7-Dimethylesculetin, another active ingredi-
ent of Yinchen (Herba Artemisia Capillaris) can normal-
ize gallbladder function, resist lipid peroxidation, and
prevent liver cell necrosis and hepatic steatosis, which
promotes liver cell regeneration and protects the integ-
rity of liver cell membranes.26,27 Danshen (Radix Salviae
Miltiorrhizae) can remove stasis and activate blood.
The combination of Danshen (Radix Salviae Miltiorrhi-
zae) and other herbs for cooling and activating blood
has an excellent therapeutic effect on jaundice. Da-
huang (Radix Et Rhizoma Rhei Palmati), which is bitter
in taste and cool in nature, can remove blood stasis,
and is considered to be the main herb for cooling
blood and treating jaundice. The combined use of Da-
huang (Radix Et Rhizoma Rhei Palmati) and other
herbs for cooling blood is also an effective therapy for
jaundice.28 Smooth defecation can block or reduce the
enterohepatic circulation of bilirubin and accelerate
the excretion of bilirubin. The combination of the
herbs in CSDPD can eliminate damp-heat and resolve
blood stasis to cure jaundice, and can complement ef-
fective Western drugs.
The results from this trial indicate that the therapeutic
effect of CSDPD combined with conventional West-
ern Medicine on chronic viral cholestatic hepatitis is su-
perior to that of conventional Western Medicine
alone. The total effective rate of CSDPD combined
with conventional Western Medicine is much higher
than that of conventional Western Medicine. This ther-
apy is safe and effective on chronic viral cholestatic hep-
atitis. However, there are also limitations to our study.
Because of small samples and short observational time,
studies with large samples and longer durations should
be conducted. Moreover, a detailed study on the mech-
anism of CSDPD should be performed.
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